Component
Confirmed disability improvement in progressive multiple sclerosis
Confirmed disability improvement in progressive multiple sclerosis. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
SPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/biotin-research/33222767.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00", "start_char": 0, "end_char": 3606, "text_sha256": "7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00"}
- experimental_model
- SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults
- exposure
- 100 mg biotin three times daily; primary improvement at month 12 confirmed at month 15
- limitations
- Pharmacologic dosing in a broader cohort; results do not address nutritional replacement in deficiency. Funding and assay-interference issues were reported.
- nutrient_topic
- Biotin research collection; topical membership is not evidence of a direct dietary effect. · Biotin
- organism
- Homo sapiens
- plain_language
- The larger confirmatory trial did not establish the hoped-for benefit.
- primary_references
- [b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1
- tissue_or_cell_type
- Progressive multiple sclerosis disability
Biotin: carboxylases, recycling, deficiency and nutrient interactions (2026-09-17) · lines 1209–1220
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults · source_derived_draft · unverified_draft
### b7-ms-confirmatory-null SPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit. Condition category: normal nutrient_topic: Biotin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The larger confirmatory trial did not establish the hoped-for benefit. organism: Homo sapiens tissue_or_cell_type: Progressive multiple sclerosis disability experimental_model: SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults limitations: Pharmacologic dosing in a broader cohort; results do not address nutritional replacement in deficiency. Funding and assay-interference issues were reported. exposure: 100 mg biotin three times daily; primary improvement at month 12 confirmed at month 15 evidence_span: {"source_cache": "artifacts/biotin-research/33222767.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00", "start_char": 0, "end_char": 3606, "text_sha256": "7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00"} [b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1
Complete structured claim and evidenceMS-SPI reported confirmed disability improvement in 13/103 biotin-treated patients versus 0/51 placebo patients at its primary endpoint (P=0.005).
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/biotin-research/27589059.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322", "start_char": 0, "end_char": 1333, "text_sha256": "78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322"}
- experimental_model
- Randomized double-blind placebo-controlled MS-SPI trial in 154 adults
- exposure
- 100 mg biotin three times daily for 12 months; later open treatment
- limitations
- Pharmacological exposure, not correction of proven nutritional deficiency. Small trial; larger confirmatory study did not reproduce efficacy.
- nutrient_topic
- Biotin research collection; topical membership is not evidence of a direct dietary effect. · Biotin
- organism
- Homo sapiens
- plain_language
- An early trial reported benefit in a subset of patients.
- primary_references
- [b7-p27589059] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. (2016). https://pubmed.ncbi.nlm.nih.gov/27589059/ DOI: 10.1177/1352458516667568
- tissue_or_cell_type
- Progressive multiple sclerosis disability
Biotin: carboxylases, recycling, deficiency and nutrient interactions (2026-09-17) · lines 1196–1207
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled MS-SPI trial in 154 adults · source_derived_draft · unverified_draft
### b7-ms-early-benefit MS-SPI reported confirmed disability improvement in 13/103 biotin-treated patients versus 0/51 placebo patients at its primary endpoint (P=0.005). Condition category: normal nutrient_topic: Biotin research collection; topical membership is not evidence of a direct dietary effect. plain_language: An early trial reported benefit in a subset of patients. organism: Homo sapiens tissue_or_cell_type: Progressive multiple sclerosis disability experimental_model: Randomized double-blind placebo-controlled MS-SPI trial in 154 adults limitations: Pharmacological exposure, not correction of proven nutritional deficiency. Small trial; larger confirmatory study did not reproduce efficacy. exposure: 100 mg biotin three times daily for 12 months; later open treatment evidence_span: {"source_cache": "artifacts/biotin-research/27589059.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322", "start_char": 0, "end_char": 1333, "text_sha256": "78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322"} [b7-p27589059] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. (2016). https://pubmed.ncbi.nlm.nih.gov/27589059/ DOI: 10.1177/1352458516667568
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.